Navigation Links
VIVUS to Present at Two Upcoming Investor Conferences
Date:3/3/2010

MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at two investment conferences during the month of March.

    The conference presentation schedule is as follows:

     Cowen and Company 30th Annual Health Care Conference
     March 10, 2010 at 9:30 a.m. ET
     The Boston Marriott Copley Place, Boston, MA

     Roth Capital Partners 22nd Annual OC Growth Stock
      Conference
     March 16, 2010 at 12:00 p.m. PT
     The Ritz Carlton, Dana Point, CA

A live audio webcast and 30-day archive of the presentations will be available on VIVUS' website at http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next- generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.
    Timothy E. Morris
    Chief Financial Officer
    650-934-5200

    Investor Relations:
    The Trout Group
    Brian Korb
    646-378-2923

    Media Relations:
    Pure Communications, Inc.
    Dan Budwick
    973-271-6085

SOURCE VIVUS, Inc.

Back to top

RELATED LINKS
http://www.vivus.com

'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
2. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
3. VIVUS to Present at Four Upcoming Healthcare Conferences
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at the Needham and Company Life Sciences Conference
6. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
7. VIVUS Reports First Quarter 2009 Financial Results and Highlights
8. PDI to Present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference
9. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Creating a Better Health Ecosystem Focus of Presentation by Aleres Dr. Gordon Norman at Population Health & Disease Management Colloquium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... December 8, 2016 Oxford Gene ... customisable SureSeq™ NGS panel range with the launch of the ... cost-effective study of variants in familial hypercholesterolemia (FH). The panel ... detection on a single small panel and allows customisation by ... includes all exons for LDLR , P ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... In response to client demand KbioBox developed a sophisticated “3 click” gene dditing ... are accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... World Technology Awards. uBiome is one of just six company finalists in the ... In addition to uBiome, companies nominated as finalists in this year’s awards include ...
Breaking Biology Technology:
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
Breaking Biology News(10 mins):